Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE-ARDS
jRCT2073260037Phase 3Not yet recruiting
- Sponsor
- Healios
- Start
- Jun 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Invimestrocel with Placebo (2 arms). Primary endpoint: Primary efficacy and safety. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
invimestrocel
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on jRCT2073260037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073260037.